奥氮平与齐拉西酮对精神分裂症患者生活质量影响的对照研究

目的比较奥氮平与齐拉西酮对精神分裂症患者的社会功能和生活质量的影响。方法将64例精神分裂症患者随机分为两组,口服奥氮平组及口服齐拉西酮组,于治疗前及出院后3、6、12个月末采用PAN-SS、TESS、WHOQOL-100及SDSS评定。结果 3、6、12个月末随访,两组PANSS总分及各因子分均较治疗前显著下降(P<0.01);同期两组之间总分及各因子分比较无显著性差异(P>0.05)。两组WHOQOL-100躯体功能、心理功能、独立性、社会关系、生活质量总评因子分均较治疗前显著提高(P<0.01),同期两组之间总分及各因子分比较无显著性差异(P>0.05)。两组SDSS的婚姻职能、社会性退缩、家庭外的社会活动、家庭内活动过少、家庭职能、个人生活自理、对外界的兴趣和关心7个因子分均显著低于治疗前(P<0.01),同期两组之间各因子分比较无显著性差异(P>0.05)。奥氮平组不良反应发生率为44.1%(15/34),齐拉西酮组不良反应发生率为46.7%(14/30),两组间比较差异无显著性(P>0.05)。结论奥氮平和齐拉西酮均能提高精神分裂症患者的生活质量。

Comparative study on the effects of olanzapine and ziprasidone on the life quality of patients with schizophrenia

Objective To investigate influence of olanzapine and ziprasidone on quality of life in patients with schizophrenia. Method A total of 64 patients with schizophrenia were randomly assigned into olanzapine group(n=34)and ziprasidone group(n=30 lost 4)for the treatment of 3,6,12 months.The positive and negative symptoms scale(PANSS) was used to evaluated the efficacy and the treatment emergent symptoms scale(TESS) was used to assess the side effects.The quality of life with the world health organization quality of life-100(WHOQOL-100)and social disabilities with the social disability screening schedule(SDSS). Results Before treatment and at the end of the 3,6 and 12 months follow-up the total and each factor scores of both groups lowered more significantly compared with pretreatment(P<0.01);The two groups showd no significant statistical differences on PANSS and TESS scores(P>0.05).Such factor scores of the WHOQOL-100 as physical and psychological function,independence,social relation and global impression of quality of life elevated more significantly compared with pretreatment in the two groups(P<0.01),such factor scores of the SDSS were significantly lower in the two groups as marital function,social retreating,social activity outside family lack of movement inside family,family function personal care external interest and care(P>0.05). Conclusion Both of olanzapine and ziprasidone could improve the life quality of patients with schizophrenia.